SA
Sana Biotechnology, Inc.
SANA · NASDAQ
$3.10 +0.32% (+$0.01)
1M -20.72%
Market Cap $862.7M
P/E Ratio -
Div. Yield -
ROE 134.49%
Bulios Fair Price
$1.65
46.8% downside
Current Price
$3.1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SANA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
30 /100
Expensive P/B 5.58x
PEG N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 31.44%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 134.49%
ROA 49.09%
Asset turnover 0.00x
Debt
78 /100
Low Current ratio 1.38x
Debt/Equity 0.48x
Net debt/EBITDA N/A
Stability
44 /100
Moderate EPS volatility 12.23%
Profitable years 0
Beta 2.13x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SANA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Steven D. Harr
Employees
142
Headquarters
Seattle
Upcoming events
05 NOV
Earnings
Upcoming earnings report